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ABSTRACT 
 
This systematic review investigated the measurement properties of disease-specific patient-
reported outcome measures used in Patellofemoral Pain Syndrome. Two independent 
reviewers conducted a systematic search of key databases (MEDLINE, EMBASE, AMED, 
CINHAL+ and the Cochrane Library from inception to August 2013) to identify relevant 
studies. A third reviewer mediated in the event of disagreement. Methodological quality was 
evaluated using the validated COSMIN (Consensus-based Standards for the Selection of 
Health Measurement Instruments) tool. Data synthesis across studies determined the level 
of evidence for each patient-reported outcome measure. The search strategy returned 2177 
citations. Following the eligibility review phase, seven studies, evaluating twelve different 
patient-reported outcome measures, met inclusion criteria. A ‘moderate’ level of evidence 
supported the structural validity of several measures: the Flandry Questionnaire, Anterior 
Knee Pain Scale, Modified Functional Index Questionnaire, Eng and Pierrynowski 
Questionnaire and Visual Analogue Scales for ‘usual’ and ‘worst’ pain. In addition, there was 
a ‘Limited’ level of evidence supporting the test-retest reliability and validity (cross-cultural, 
hypothesis testing) of the Persian version of the Anterior Knee Pain Scale. Other 
measurement properties were evaluated with poor methodological quality, and many 
properties were not evaluated in any of the included papers. Current disease-specific 
outcome measures for Patellofemoral Pain Syndrome require further investigation. Future 
studies should evaluate all important measurement properties, utilising an appropriate 
framework such as COSMIN to guide study design, to facilitate optimal methodological 
quality. 
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INTRODUCTION 54 
 55 
Patellofemoral pain syndrome (PFPS) is a common knee disorder, with a typical 56 
pattern of symptoms characterised by anterior peripatella or retropatella knee pain 57 
(Heintjes et al., 2009; Collins et al., 2010; Hossain et al., 2011). Aggravating factors 58 
include activities or movements which either increase patellofemoral joint 59 
compression and/or produce mechanical forces in the surrounding soft tissue 60 
structures; for example: ascending/descending stairs, sitting with a flexed knee for 61 
prolonged periods, squatting, running, jumping or kneeling (Witvrouw et al., 2000; 62 
Crossley et al., 2002; Barton et al., 2008; Thijs et al., 2008; Tan et al., 2010). As 63 
many of these activities are an important part of daily life, PFPS may have a 64 
considerable impact on an individual’s wellbeing (Collins et al., 2008; Tan et al., 65 
2010). This impact may be especially debilitating as PFPS symptoms often reoccur, 66 
becoming chronic (Nimon et al., 1998; Stathopulu and Baildam, 2003; Collins et al., 67 
2008; Boling et al., 2010). 68 
 69 
Whilst the aetiology of PFPS is debated, there is some consensus that its 70 
development may be secondary to a functional or structural mal-alignment at the 71 
patellofemoral joint, or of the lower extremity as a whole (Powers, 2003; Barton et al., 72 
2008; Heintjes et al., 2009; Carry et al., 2010; Hossain et al., 2011). There may be 73 
multiple interacting factors which cause mal-alignment, such as muscle strength or 74 
timing issues, altered tissue extensibility or bony morphology (Powers, 2003; Barton 75 
et al., 2008; Heintjes et al., 2009; Bennell et al., 2010). 76 
 77 
Physiotherapy is the most common intervention in PFPS (Crossley et al., 2001; 78 
Heintjes et al., 2003), however, there is no clear consensus regarding the optimal 79 
components of a management programme. As a consequence, a wide variety of 80 
treatment techniques are employed by therapists including: quadriceps 81 
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strengthening, vastus medialus obliques (VMO) muscle retraining, biofeedback, hip 82 
muscle strengthening, proximal strengthening, spinal manipulation, mobilisation, 83 
taping, knee supports, foot orthoses and stretching of the hamstrings, illiotial band, 84 
patella retinaculum or anterior hip (Crossley et al., 2002; Iverson et al., 2008; 85 
Heintjes et al., 2009; Earl and Hoch, 2011; Hossain et al., 2011; Callaghan and Selfe, 86 
2012). In the absence of guidelines outlining the most favourable PFPS treatment 87 
options, physiotherapists should appraise their own management, utilising high 88 
quality, disease-specific, PFPS outcome measures to guide and evaluate patient 89 
care, so they may deliver efficacious treatment tailored to the individual (DoH, 2010; 90 
CSP, 2012; HCPC, 2013). 91 
 92 
A number of patient-reported outcome measures (PROMs) have been developed to 93 
assess symptoms and function in patients with PFPS. These disease-specific 94 
measures are designed to be more sensitive to change in their target population than 95 
region-specific measures, which evaluate general knee disorders. When making the 96 
choice of which PROM to use in practice, it is important to examine their respective 97 
measurement properties, so that the optimal instrument can be confidently employed. 98 
These properties should at least satisfy existing minimum standards for PROMs, 99 
such as those presented by the International Society for Quality of Life research 100 
(Reeve et al., 2013).  Previous systematic reviews that have evaluated the 101 
measurement properties of knee PROMs, have tended to focus on region-specific 102 
measures used in general knee conditions (Bellamy et al., 1997; Sun et al., 1997; 103 
Wang et al., 2010), or non-PFPS-specific musculoskeletal disorders (Smith et al., 104 
2008; Howe et al., 2012), and not all reviews have used a validated tool to determine 105 
the quality of the included studies, for example, the COSMIN (Consensus-based 106 
Standards for the Selection of Health Measurement Instruments) tool (Mokkink et al., 107 
2010a) or OMERACT (Outcome Measures in Rheumatology) filter (Boers et al., 108 
1998). The purpose of this study was to evaluate the measurement properties of 109 
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disease-specific PROMs for PFPS, using a validated measure of methodological 110 
quality. 111 
  112 
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METHODOLOGY 113 
 114 
Design 115 
A systematic review of outcomes was conducted according to a pre-defined protocol 116 
informed by the PRISMA guidelines (Liberati et al., 2009), the Cochrane Handbook of 117 
Systematic Review Interventions (Higgins and Green, 2011) and the COSMIN group 118 
(Mokkink et al., 2010b). 119 
 120 
Search strategy 121 
The MEDLINE, EMBASE, AMED, CINHAL+ and Cochrane Library electronic 122 
databases were searched from inception to August 2013 (the MEDLINE search 123 
strategy is presented in Appendix I). All records were downloaded into Endnote© 124 
version 15, and duplicates removed. Two authors (DK, CL) independently screened 125 
all citations by title/abstract, before retrieving potentially eligible full text articles for 126 
review. Disagreements were resolved through discussion, with a third reviewer on 127 
hand to mediate if required. The strength of agreement between investigators was 128 
established using Cohen’s kappa statistic (Cohen, 1960) and interpreted using set 129 
criteria (Landis and Koch, 1977).  Remaining articles were subjected to a citation 130 
search. Finally, a hand-search of all reference lists was conducted. 131 
 132 
Identification of eligible studies 133 
Full text original articles were included if they evaluated at least one PROM 134 
measurement property (reliability, validity, responsiveness or interpretability (Mokkink 135 
et al., 2010a)) in a cohort of PFPS patients. There are no universally agreed 136 
diagnostic criteria for PFPS, therefore, this review used criteria employed by several 137 
high-quality randomised controlled trials, each demonstrating treatment efficacy in a 138 
PFPS cohort (Collins et al., 2008; van Linschoten et al., 2009; Collins et al., 2010). 139 
Thus, studies had to include participants that presented with a main complaint of 140 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5
patellofemoral pain (defined as anterior peripatellar or retropatellar knee pain) with 141 
symptoms that were provoked by at least two of the following: prolonged sitting or 142 
kneeling, stair walking, running, squatting, hopping, a positive Clarke’s sign or grind 143 
test, a positive patellar compression test and recognisable painful symptoms on 144 
palpation of the patellar facets (Collins et al., 2008; Syme et al., 2009; van 145 
Linschoten et al., 2009). Internationally agreed definitions for each measurement 146 
property Mokkink et al.,(2010a) informed the eligibility review. Non-English language 147 
papers were excluded. 148 
 149 
Data Extraction 150 
Two authors (AG, CL) independently extracted data regarding the following 151 
measurement properties: reliability, internal consistency, measurement error), validity 152 
(including content, construct, criterion and cross-cultural validity), responsiveness 153 
and interpretability (Mokkink et al., 2010a). Disagreements were resolved through 154 
discussion with the intervention of a third author (DK) if needed.  155 
 156 
Measurement Properties 157 
Reliability examines the degree to which a measurement is free from error, and can 158 
be considered in three categories: test-retest reliability (the degree to which results 159 
can be replicated over time within a stable environment), this can be further divided 160 
into inter-rater reliability (between individuals) and intra-rater reliability (within the 161 
same individual); internal consistency (correlation between items that are 162 
interrelated); and measurement error (systematic and random error within a patient’s 163 
outcome score that is not attributed to a true change) (Mokkink et al., 2010b).  164 
Validity encompasses: content validity (is the PROM an adequate reflection of the 165 
construct to be measured); construct validity (how a PROM performs against pre-166 
defined hypotheses); criterion validity (how a PROM compares to a ‘gold standard’ if 167 
available); and cross-cultural validity (how well the translated PROM reflects the 168 
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original version) (Mokkink et al., 2010b). Responsiveness is the ability of an outcome 169 
measure to detect a clinically meaningful change in a patient’s condition over time 170 
(Mokkink et al., 2010b).  In addition, a PROM must demonstrate adequate 171 
interpretability, to ensure that the meaning and significance of changes in score can 172 
be easily understood (Mokkink et al., 2010a). 173 
 174 
Quality assessment and evidence synthesis 175 
Methodological quality of the included studies was evaluated in order to determine 176 
their trustworthiness. Two investigators (AG, CL) independently assessed each 177 
study, rating the quality of methods employed to evaluate individual measurement 178 
properties, using the validated COSMIN framework (Mokkink et al., 2010a). 179 
Disagreements were resolved through discussion with a third author (DK). Papers 180 
were rated using a 4-point scale (‘poor’, ‘fair’, ‘good’, ‘excellent’) (Terwee et al 2012). 181 
Synthesis across studies combined findings for each measure and measurement 182 
property, taking into account the quality of studies, to determine the level of evidence 183 
for each PROM (Schellingerhout et al., 2012). The overall level of evidence was 184 
rated as ‘strong’, ‘moderate’, ‘limited’ or ‘conflicting’, in-line with the criteria proposed 185 
by the Cochrane Back Review Group (van Tulder et al., 2003).  186 
 187 
  188 
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RESULTS 189 
 190 
Study selection 191 
The search strategy returned 2177 citations. 2155 studies were excluded by 192 
title/abstract and 22 full-text articles were retrieved for further review. Of these, 15 193 
full-text articles were excluded as they utilised non-PFPS cohorts, PFPS was not the 194 
major complaint of the participants, or because the PFPS diagnostic criteria used by 195 
the paper did not meet the defined standards, or was missing altogether. Inter-rater 196 
agreement between the investigators during title/abstract screening was ‘good’ 197 
(k=0.68, 95% CI 0.557-0.806) (Cohen, 1998). No additional full-text articles were 198 
included following either the citation search or the hand search of reference lists, 199 
therefore, 7 papers were included in the final analysis (Figure. 1). The included 200 
studies evaluated 12 PROMs, including: the Activity of Daily Living Scale (ADLS) 201 
(Irrgang et al., 1998); the Eng and Pierrynowski Questionnaire (EPQ), also known as 202 
the Visual Analogue Pain Scale during Activity (Eng and Pierrynowski, 1993); the 203 
Flandry Questionnaire (Flandry et al., 1991); the Kujala/Anterior Knee Pain Scale 204 
(AKPS) (Kujala et al., 1993); the Modified Functional Index Questionnaire (MFIQ) 205 
(Chesworth et al., 1989); the Persian Version Kujala/AKPS (Negahban et al., 2012); 206 
the Patellofemoral Function Scale (PFS) (Reid, 1992); the PFPS Severity Scale 207 
Syndrome (PSS) (Laprade and Culham, 2002); the Visual Analogue Pain Scale 208 
(VAS), also referred to as the Numerical Pain Rating Score (NPRS); and the Visual 209 
Analogue Pain Scales for least pain (VAS-L), usual pain (VAS-U) and worst pain 210 
(VAS-W). 211 
 212 
Study characteristics 213 
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Study characteristics are presented in Table 1. The 7 studies examined 384 214 
symptomatic PFPS subjects, largely recruited from the general population, with 1 215 
study recruiting from the military (Laprade and Culham, 2002). The mean age of 216 
participants ranged from 23.8 to 32 years old. Average duration of symptoms was 217 
reported in 3 papers (Bennell et al., 2000; Crossley et al., 2004; Negahban et al., 218 
2012) and ranged from 12.0 to 38.6 months. No study provided details regarding the 219 
severity of participant symptoms. Details of each PROM evaluated across the 7 220 
studies is presented in Table 2. Measurement property data are presented in Table 221 
3. The methodological quality of the studies is presented in Table 4 and the results, 222 
presented per PROM, are discussed below. 223 
 224 
Activity of Daily Living Scale (ADLS) 225 
Contains 14 items investigating general daily activities and specific functional tasks 226 
(e.g. stair descent). Each item is scored 0-5 to provide an overall percentage score. 227 
Higher scores indicate better functioning. One study (Piva et al., 2009) found the 228 
ADLS responsive, demonstrating a moderate change in score (effect size 0.63). 229 
However, this property was evaluated with ‘poor’ methodological quality. 230 
 231 
Eng and Pierrynowski questionnaire (EPQ)  232 
An activity-related pain-rating tool using a 0-10 visual analogue scale. Higher scores 233 
indicate more pain. Two studies (Bennell et al., 2000; Crossley et al., 2004) 234 
supported reliability (ICC3,1 0.83-0.92), one study (Crossley et al., 2004) found the 235 
EPQ responsive (RTE 0.76), and one study (Bennell et al., 2000) reported a Minimal 236 
Clinically Important Difference (MCID) of 14 points (23%). However, measurement 237 
properties were evaluated with ‘poor’ methodological quality. Structural validity of the 238 
EPQ was supported by Bennell et al. (2000), with a ‘moderate’ correlation (r=0.66) 239 
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with the Flandry questionnaire. This property was evaluated with ‘moderate’ 240 
methodological quality.  241 
 242 
Flandry Questionnaire 243 
Consists of 28 visual analogue scale items which investigate the severity of knee 244 
symptoms and the ability to perform physical activities. One study (Bennell et al., 245 
2000) supported test-retest reliability (ICC3,1 = 0.95) and structural validity (r = 0.66) 246 
and also reported a Standard Error of Measurement (SEM) of 34 points (27.6%). 247 
However, these measurement properties were evaluated with ‘poor’ methodological 248 
quality. 249 
 250 
Kujala/Anterior Knee Pain Scale (AKPS)  251 
A 13-item knee function questionnaire, scored out of 100, with higher scores 252 
indicating less disability. Two studies (Bennell et al., 2000; Crossley et al., 2004) 253 
supported reliability (ICC3,1  = 0.81-0.90) and responsiveness (treatment effect size = 254 
1.15 for responders), however, these measurement properties were evaluated with 255 
‘poor’ methodological quality. Bennell et al. (2000) reported a moderate correlation 256 
for structural validity (r = 0.58); this property was evaluated with ‘good’ 257 
methodological quality.  258 
 259 
Modified Functional Index Questionnaire (MFIQ) 260 
Consists of 8 items that measure the ability to perform various functional activities. A 261 
maximum score of 16 indicates optimal functioning. Three studies (Chesworth et al., 262 
1989; Bennell et al., 2000; Crossley et al., 2004) supported test-retest reliability (ICC 263 
= 0.48; ICC3,1 = 0.49-0.94); one study (Harrison et al., 1995) demonstrated a ‘very 264 
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good’ level of internal consistency (pre-treatment α = 0.85 and post-treatment α = 265 
0.88); one study (Bennell et al., 2000) reported the MCID as 2.8 points (16%); two 266 
studies (Harrison et al., 1995; Crossley et al., 2004) found the MFIQ responsive with 267 
a moderate effect sizes (0.49 and 0.59)., However, all these properties were 268 
evaluated with ‘poor’ methodological quality. Bennell et al. (2000) supported the 269 
validity of the MFIQ, evidenced by a moderate correlation (r = -0.66); this property 270 
was evaluated with ‘good’ methodological quality. 271 
 272 
The PFPS Severity Scale Syndrome (PSS) 273 
A 10 item visual analogue instrument, examining the effect of PFPS on an 274 
individual’s functional activities. One study (Laprade and Culham, 2002) supported 275 
the test-retest reliability (r = 0.95), however, this property was evaluated with ‘poor’ 276 
methodological quality. 277 
 278 
Visual Analogue Scale (VAS)/ Numerical Pain Rating Scale 279 
This scale - scored from 0 (no pain) to 10 (max pain) - evaluates levels of pain. Other 280 
versions include: (1) VAS-L (pain at its least), (2) VAS-U (usual level of pain), and (3) 281 
VAS-W (pain when at its worst). Five studies (Chesworth et al., 1989; Harrison et al., 282 
1995; Bennell et al., 2000; Crossley et al., 2004; Piva et al., 2009) supported both 283 
test-retest reliability (ICC = 0.56-0.77; ICC3,1 = 0.56-0.79) and responsiveness (effect 284 
size for improved responders = 0.70-1.22; RTE = 0.95-1.09) of the VAS, VAS-L, 285 
VAS-U and VAS-W, however, these properties were evaluated with ‘poor’ 286 
methodological quality in all studies. One study (Bennell et al., 2000), found a 287 
minimum change of 3.3cm (33%) on the VAS-U was required to detect a real change 288 
in a patient’s condition, again methodological quality was ‘poor’.   289 
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 290 
Bennell et al. (2000) established that the VAS-U and VAS-W were moderately 291 
correlated (r = 0.63), providing evidence of their structural validity; this property was 292 
evaluated with ‘good’ methodological quality. 293 
 294 
The Patellofemoral Function Scale (PFS) 295 
Contains 9 items, scored from 0-100, examining both PFPS signs/symptoms and the 296 
ability of the patient to perform functional activities; higher scores indicating less 297 
disability. One study (Harrison et al., 1995) found the scale was responsive (effect 298 
size = 0.81 for responders) and demonstrated a ‘minimally acceptable’ to 299 
‘acceptable’ internal consistency (pre-treatment α = 0.65 and post-treatment  α = 300 
0.77), however, these properties were evaluated with ‘poor’ methodological quality.  301 
 302 
Persian Version Kujala/AKPS 303 
One study (Negahban et al., 2012) reported ‘excellent’ test-retest reliability (ICC2,1 =  304 
0.96) and confirmed the accuracy of the hypothesis that the Persian Kujala 305 
questionnaire would correlate more highly with the SF-36 physical questionnaire than 306 
the SF-36 mental questionnaire (correlation 0.34-0.51 and 0.25-0.37 respectively); 307 
these properties were evaluated with ‘fair’ methodological quality. Negahban et al. 308 
(2012) also reported high levels of internal consistency (α = 0.81), however, for this 309 
component of the study, methodological quality was ‘poor’. Cross-cultural validity was 310 
also examined with the authors concluding that no major translation modifications 311 
were required, this aspect of the study demonstrated ‘good’ methodological quality 312 
(Negahban et al, (2012).  313 
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 314 
As this questionnaire was a translated version, it was not synthesised with English 315 
language AKPS as the respective findings may not be directly comparable 316 
(Schellingerhout et al., 2012), hence presented separately in Table 5.  317 
 318 
Synthesis of results across studies 319 
Synthesis of results for each questionnaire with the associated level of evidence is 320 
presented in Table 5. There was a ‘moderate’ level of evidence to support the 321 
structural validity of the: EPQ, Flandry Questionnaire, AKPS, MFIQ, VAS-U and VAS-322 
W. In addition, there was a ‘limited’ level of evidence supporting the reliability (test-323 
retest) and validity (cross-cultural and hypothesis testing) of the Persian version of 324 
the AKPS, based on the findings of one paper. 325 
 326 
It was not possible to identify supporting evidence for the following PROM 327 
measurement properties due to poor methodological quality across the included 328 
papers: ADLS (responsiveness); EPQ and AKPS (test-retest reliability, measurement 329 
error, responsiveness); Flandry Questionnaire (test-retest reliability, measurement 330 
error); MFIS (internal consistency, test-retest reliability, measurement error, 331 
responsiveness); PSS (internal consistency); VAS and VAS-L (test-retest reliability, 332 
responsiveness); VAS-U (test-retest reliability, measurement error, hypothesis 333 
testing, responsiveness); VAS-W (internal consistency, test-retest reliability, 334 
responsiveness).  335 
 336 
There was no information available for the following PROM measurement properties: 337 
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ADLS (internal consistency, test-retest reliability, measurement error, structural 338 
validity, hypothesis testing); EPQ and AKPS (internal consistency, hypothesis 339 
testing); Flandry Questionnaire (internal consistency, hypothesis testing, 340 
responsiveness); MFIQ (hypothesis testing); PSS (test-retest reliability, measurement 341 
error, structural validity, hypothesis testing, responsiveness); VAS and VAS-L 342 
(internal consistency, measurement error, structural validity, hypothesis testing); 343 
VAS-U (internal consistency) and VAS-W (internal consistency, hypothesis testing). 344 
In addition, no PROM was examined for the measurement property of interpretability.  345 
DISCUSSION 346 
 347 
The objective of this systematic review was to evaluate the measurement properties 348 
of disease-specific PROMs for PFPS, to aid clinicians in choosing the best 349 
instrument to inform patient management. Unfortunately, the poor methodological 350 
quality with which measurement properties were evaluated across the PROMs, 351 
makes recommending an optimal instrument problematic. 352 
 353 
Principal findings 354 
We found a ‘moderate’ level of evidence to support the construct validity (structural 355 
validity) of six PROMs: the Flandry Questionnaire, AKPS, MFIQ, EPQ, VAS-U and 356 
VAS-W. We also found a ‘limited’ level of evidence supporting the reliability (test-357 
retest) and validity (cross-cultural and hypothesis testing) of the Persian version of 358 
the AKPS, based on the findings of one paper. Unfortunately, many other important 359 
PROM measurement properties were either evaluated with poor methodological 360 
quality (e.g. measurement error), or were not evaluated at all (e.g. interpretability). 361 
Common methodological shortcomings included: small sample sizes, absent a priori 362 
hypotheses, missing details/references for comparator instruments during the 363 
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evaluation of responsiveness and a failure to check the uni-dimensionality of a scale 364 
prior to the evaluation of internal consistency. 365 
 366 
Structural validity, as a component of construct validity, has been identified as a 367 
critical element of the overall validity of a PRO instrument (Reeve et al., 2013), it is 368 
therefore encouraging that over half of the tools we investigated demonstrated this 369 
feature. Unfortunately, no measure was able to satisfy all of the recently agreed 370 
minimum standards for PROMs advocated by the International society for Quality of 371 
Life research (Reeve et al., 2013).  372 
 373 
Comparing these results to those of other authors is difficult. As mentioned 374 
previously, there is a lack of systematic reviews focusing on PFPS-specific PROMs 375 
used exclusively in PFPS cohorts. Howe et al. (2012) did review the measurement 376 
properties of a number of PROMs that arguably could be employed in PFPS, but did 377 
so alongside other musculoskeletal disorders, including osteoarthritis, ligament 378 
injuries and meniscal lesions. Although the results are not directly comparable, the 379 
findings from this study appear similar to ours with regard to the AKPS PROM, which 380 
was reviewed in both studies. Using the OMERACT filter, Howe et al. 2012 381 
determined that the tool demonstrated construct validity, however, they also 382 
supported its responsiveness, which the current study did not. Our use of the 383 
COSMIN tool instead of the OMERACT filter may explain this difference. Finally, 384 
Smith and colleagues (2008) evaluated several outcome measures used to assess 385 
patellar instability, of which, only the AKPS was included in our study. The findings 386 
from both reviews are consistent, namely that poor methodological quality precluded 387 
definitive conclusions regarding the measurement properties of the PROMs they 388 
investigated. 389 
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 390 
One of the main purported benefits of disease-specific PROMs is that they may be 391 
more sensitive to subtle changes in a patient’s condition (i.e. more responsive) than 392 
more generic tools (Garratt et al., 2001; Walsh et al., 2003).  It is particularly 393 
disappointing, therefore, that evidence of responsiveness was lacking in the PROMs 394 
we evaluated. Until such time as they are evaluated and validated with greater 395 
methodological quality, it is not possible to recommend a disease-specific PROM 396 
over an evidence-supported region-specific measure. 397 
 398 
Strengths and limitations 399 
A strength of this study is its use of systematic methods to investigate the 400 
measurement properties of PROMs employed in PFPS, taking into account the 401 
quality of the methods used in the included studies. A limitation is, as there are no 402 
universally agreed diagnostic criteria for PFPS, this review used criteria employed by 403 
recent high-quality randomised controlled trials. This may have led to the exclusion of 404 
some articles that were potentially relevant, but used different diagnostic parameters. 405 
Further work is needed to develop definitive PFPS diagnostic criteria. 406 
  407 
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CONCLUSIONS 408 
 409 
Several PROMs used in PFPS demonstrate structural validity including: the Flandry 410 
Questionnaire, AKPS, MFIQ, EPQ, VAS-U, and VAS-W. In addition there is limited 411 
level of evidence supporting the test-retest reliability and validity (cross-cultural and 412 
hypothesis testing) of the Persian version of the AKPS, based on one study. 413 
However, no instrument possesses supporting evidence for all important 414 
measurement properties (Reeve et al., 2013). The measurement properties of 415 
PROMs in PFPS are commonly evaluated with poor methodological quality, and 416 
many are yet to be investigated. Current PFPS measures should be subjected to 417 
further scrutiny and future studies should evaluate all important measurement 418 
properties, utilising an appropriate framework such as COSMIN to guide study 419 
design, to facilitate optimal methodological quality. 420 
 421 
  422 
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Table 1  588 
Characteristics of Included Studies 589 
 
Study 
 
Country 
 
Subjects 
(num. of females) 
 
Participants 
Mean (SD or range) 
 
Duration of Symptoms (months) 
Mean (SD) unless stated. 
Bennell et al., 2000a Australia 50 (33) 23.8 ± 8.9 yrs  17.1 (25.2) 
Chesworth et al., 1989a Canada 18 (12) 29.0 yrs (20-50)  not reported 
Crossley et al., 2004a  Australia 71 (46) 27.5 yrs (14-40)  38.6 (42.6) [Rx Gr] 
31.1 (32.2) [Placebo Gr] 
Harrison et al., 1995a Canada 56  (7) 24.8 yrs (12-41)  not reported 
Laprade and Culham, 2002b Canada 29 (71) 32.0 yrs (20-48) Range: 3-72 
Negahban et al., 2012a Iran 100 (0) 25.3 ± 7.0 yrs  Median & interquartile range: 12 (6-24) 
Piva et al., 2009c USA 60 (33) 29.9 ± 9.6 yrs  Distribution: 1-3 (38%); 4-6 (22%), 7-12 
(10%), 13-24 (18%), >25 (12%). 
Settings: a = General population, b = Military population, c  = Unknown population. 590 
.  591 
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Table 2 592 
Characteristics of Patient reported Outcome Measures 593 
Instrument Name Study ID Summary of Instrument Scoring Method 
Activity of Daily 
Living Scale (ADLS) 
Piva et al., 2009 14-item scale assessing how 
patient’s knee symptoms affect 
their ability to perform general 
daily activities (6 items) and 
specific functional tasks (8 
items).   
Each item scored 0-5 (0 = 
unable; 5 = no difficulty to 
perform); max score = 70. 
Percentage calculated 
(score/70 x 100). 
Eng & Pierrynowski 
Questionnaire/Visual 
Analogue Pain Scale 
during Activity (EPQ) 
Bennell et al., 2000; 
Crossley et al., 2004 
Visual rating scale that is used 
to indicate the perception of the 
level of pain during activity. 
10cm horizontal line drawn 
with annotations along the line 
for example ‘no pain’. 
Score is the measurement 
from left hand side to patient’s 
mark. 
Flandry 
Questionnaire 
Bennell et al., 2000 Questionnaire to evaluate 
subjective components of 
unspecific knee complaints; 28  
items relating to severity of 
symptoms and the ability to 
perform activities. 
Each item (i.e. 28) scored on a 
VAS (0 – 10); max score = 
280. 
 
 
Kujala/Anterior Knee 
Pain Scale (AKPS) 
Bennell et al., 2000; 
Crossley et al., 2004 
13 item multiple-choice PFPS 
questionnaire relating to the 
patient’s knee function.   
3-5 response choices 
depending on item; each 
response allocated a score.  
Scores vary between 0 and 10;  
max score = 100. 
Modified Functional 
Index Questionnaire 
(MFIQ) 
Bennell et al., 2000; 
Chesworth et al., 
1989; 
Crossley et al., 
2004; 
Harrison et al., 1995 
8-item questionnaire relating to 
the ability to perform functional 
activities on that day. 
Each item scored on a 3-point 
scale: 0 – unable to do; 1 – 
can do with a problem; 2 – no 
difficulty; max score = 16. 
Persian Version 
Kujala 
Negahban et al., 
2012 
Translated version of Kujala – 
Persian (more info see Kujala) 
Same as Kujala. 
The Patellofemoral 
Function Scale 
(PFS) 
Harrison et al., 1995. 16 multiple-choice item scale 
with 9 PROs and 7 CROs. Items 
are based on pain, ability to 
perform functional activities and 
cardinal signs associated with 
Items have multiple choice 
answers (e.g. Jogging – 6 = no 
restriction; 0 = restricted.) 
Response scores  vary 
between 0 and 10; max score 
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PFPS. = 100. 
The PFPS Severity 
Scale Syndrome 
(PSS) 
Laprade and 
Culham, 2002 
10 items assessing pain and the 
ability to perform functional 
activities.  
Each item scored using 10cm 
VAS; max score = 100. 
Visual Analogue 
Pain Scale (VAS)/ 
Numerical Pain 
Rating Score 
(NPRS) 
Chesworth et al., 
1989; 
Piva et al., 2009  
Visual rating scale that is used 
to indicate the perception of the 
current level of pain. 
As in Eng/VAS-A 
Visual Analogue 
Pain Scale when 
Least pain (VAS-L) 
Harrison et al., 1995 Visual rating scale that is used 
to indicate the perception of the 
level of pain when at its least. 
As in Eng/VAS-A 
Visual Analogue 
Pain Scale when 
Usual pain (VAS-U) 
Bennell et al., 2000; 
Crossley et al., 
2004; 
Harrison et al., 1995 
Visual rating scale that is used 
to indicate the perception of the 
usual level of pain i.e. average 
level of pain. 
As in Eng/VAS-A 
Visual Analogue 
Pain Scale when 
Worst pain (VAS-W) 
Bennell et al., 2000; 
Crossley et al., 
2004; 
Harrison et al., 1995 
Visual rating scale that is used 
to indicate the perception of the 
level of pain when at its worst. 
As in Eng/VAS-A 
PFPS – Patellofemoral Pain Syndrome; VAS – Visual Analogue Scale; PRO – 594 
Patient-Reported Outcome; CRO – Clinician-Reported Outcome. 595 
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Table 3 
Results of the measurement properties for the patient reported outcome measures. 
 
Study ID 
 
Study 
size 
Measurement Property 
Internal 
Consistency 
Test-Retest Reliability (& 
Standard Error of 
Measurement) 
Validity 
 
Responsiveness 
ADLS  
     
Piva et al., 2009 n = 60 _ _ _ Effect Size:  1.19(I), 0.03 (NI),  
                     0.63 (overall) 
Guyatt Index: 1.4 
Area under ROC curve: 0.83 
MCID = 7.1% (5 pts) 
      
EPQ  
     
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.92 
Paired t test = 2.298 (0.03)a 
SEM: 4.8 (14 points; 23%) 
vs Flandry,  
Pearson r = 0.66 (BC)S 
_ 
Crossley et al., 2004 n = 71 _ ICC(3,1) = 0.83 
Paired t test = -0.10 (0.92)a 
 
_ Median score: 1(NI) vs -19(I) 
RTE =  0.76  
RE  = No figure provided 
 
     
Flandry  
     
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.95 
Paired t test = 0.991 (0.33)a 
SEM: 120 (34 points; 27.6%) 
vs Eng,   
Pearson r = 0.66 (BC)S 
_ 
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Kujala/AKPS   
   
 
 
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.90  
Paired t test = -0.673 (0.51)a 
SEM: 4.7 (13 points; 14%) 
vs FIQ,  
Pearson r = 0.58 (BC)S 
_ 
Crossley et al., 2004 n = 71 _ ICC(3,1) = 0.81 
Paired t test = -1.35 (0.20)a 
 
_ Median score: 2(NI) vs 15.5(I) 
RTE = 1.15 
RE = 1.24 
 
     
MFIQ  
     
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.94 
Paired t test = 1.796 (0.09)a 
SEM:  1.0 (2.8 points; 16%)  
vs Flandry,  
Pearson r = -0.66 (BC)S 
_ 
Chesworth et al., 1989 n = 18 _ ICC = 0.483  _ ANOVAa: F = 21.09; 2,20 df; p<0.001  
Newman-Keulsa: Pre-Rx: p >0.05 
                            Post-Rx: p<0.01 
Crossley et al., 2004 n = 71 _ ICC(3,1) = 0.49  
Paired t test = -1.34 (0.20)a  
 
_ Median score: -0.5(NI) vs 3(I) 
RTE  = 0.49  
RE = 0.18 
Harrison et al., 1995 n = 56 Pre-Rx:  
Cronbach’s  α = 
0.85 
Post-Rx: 
Cronbach’s  α = 
0.88 
Pre-Rx: Spearman r = 0.69-
0.77  
Post-Rx: Spearman r = 0.84-
0.92  
_ ANOVAa: Pre-Rx:  no significant 
differences (p<0.05) & post Rx: 
significant differences (p<0.05) 
between I & NI.  
Effect Size: Pre-Rx: -0.17 
Effect Size: Post-Rx: 0.59(I), -0.50(NI) 
 
     
Persian Version Kujala 
 
     
Negahban et al., 2012 n = Cronbach’s α = ICC(2,1) = 0.96  Correlations higher _ 
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100 0.81  between Kujala & SF36  
physical than Kujala & 
SF36 mentalH 
      
PFS 
     
Harrison et al., 1995 N = 
56 
Pre-Rx:  
Cronbach’s  α = 
0.65 
Post-Rx: 
Cronbach’s  α = 
0.77 
  Effect Size: Pre-Rx: no results 
Effect Size: Post-Rx: 0.81(I), -0.31(NI) 
PSS 
 
     
Laprade and Culham, 
2002 
n = 29 Spearman r = 
0.95 
 
_ _ _ 
 
     
VAS/ NPRS 
 
     
Chesworth et al., 1989 n = 18 _ ICC = 0.603  _ ANOVAa: F = 19.72; 2,20 df; p< 0.001 
Newman-Keulsa: Pre-Rx: p >0.05 
Piva et al., 2009 n = 60 _ _ _ Effect Size: 1.22(I), 0.26(NI) 
Guyatt Index: 1.9 
Area under ROC curve: 0.84 
MCID = 1.2 pts 
      
VAS-L 
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Harrison et al., 1995 n = 56 _ Pre-Rx:  ICC = 0.64  
Post-Rx: ICC = 0.74  
_ ANOVAa: Pre-Rx:  no significant 
differences (p<0.05) & post Rx: 
significant differences (p<0.05) 
between I & NI 
      
VAS-U 
 
     
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.77 
Paired t test = 0.517 (0.61)a 
SEM: 1.2 (3.3cm; 30%) 
 
vs VAS-W, 
Pearson r = 0.63 (BC)S 
_ 
Crossley et al., 2004 n = 71 _ ICC(3,1) = 0.56 
Paired t test = -0.40 (0.69)a 
 
_ Median score: -1(NI) vs -3(I) 
RTE = 0.95 
RE = 1 
Harrison et al., 1995 n = 56 _ Pre-Rx:  ICC = 0.58  
Post-Rx:  ICC = 0.77  
_ ANOVAa: Pre-Rx:  no significant 
differences (p<0.05) & post Rx: 
significant differences (p<0.05) 
between I & NI  
Effect Size: Pre-Rx: -0.20 
Effect Size: Post-Rx: 0.75(I), -0.15(NI) 
 
     
VAS-W 
 
     
Bennell et al., 2000 n = 50 _ ICC(3,1) = 0.79 
Paired t test = 3.301 (0.03)a 
SEM: 1.1 (3.0cm; 30%) 
vs VAS-U,  
Pearson r = 0.63 (BC)S 
_ 
Crossley et al., 2004 n = 71 _ ICC(3,1) = 0.76 _ Median score: 0.5 (NI) vs -3.5(I) 
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S
 – Structural validity; H – Hypothesis validity. 
ROC = Reciever Operating Characteristic; MCID = minimum clinical important difference; ICC = Intraclass Correlation Coefficient; SEM = 
Standardised Error of Measurement; BC = Best Correlation; NI = Not Improved; I = Improved; RTE = Relative Treatment Effect; RE = Relative 
Efficiency; ANOVA = A repeated measures analysis of variance;  df = degrees of freedom; CI = Confidence Interval; Rx  =treatment; WOMAC  
= Western Ontario and McMaster Universities;  
a Statistical Significant Difference ( p = 0.05). 
  
Paired t test  = 1.65 (0.12)a 
 
RTE = 1.09 
RE = No figure provided 
Harrison et al., 1995 n = 56 _ Pre-Rx: ICC = 0.56  
Post-Rx: ICC = 0.70  
_ ANOVAa: Pre-Rx:  no significant 
differences (p<0.05) & post Rx: 
significant differences (p<0.05) 
between I & NI.  
Effect Size: Pre Rx: 0.02 
Effect Size: Post Rx: 1.15(I), 0.09(NI) 
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Table 4  
Methodological quality of each study per measurement property and patient reported outcome measure 
 
Measurement Property  
 
Internal 
Consistency 
Test-retest 
Reliability 
Measurement 
Error 
Validity Responsiveness Interpretability 
ADLS  
      
Piva et al., 2009 _ _ _ _ Poor _ 
EPQ  
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Crossley et al., 2004 _ Poor _ _ Poor _ 
Flandry  
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Kujala/AKPS   
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Crossley et al., 2004 _ Poor _ _ Poor _ 
MFIQ  
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Chesworth et al., 1989 _ Poor _ _ Poor _ 
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Crossley et al., 2004 _ Poor _ _ Poor _ 
Harrison et al., 1995 Poor Poor _ _ Poor _ 
Persian Version Kujala* 
      
Negahban et al., 2012 Poor Fair _ FairH; GoodC _ _ 
PFS** 
      
Harrison et al., 1995 Poor _ _ _ Poor _ 
PSS 
      
Laprade and Culham, 2002 _ Poor _ _ _ _ 
VAS/ NPRS 
      
Chesworth et al., 1989 _ Poor _ _ Poor _ 
Piva et al., 2009 _ _ _ _ Poor _ 
VAS-L 
      
Harrison et al., 1995 _ Poor _ _ Poor _ 
VAS-U 
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Crossley et al., 2004 _ Poor _ _ Poor _ 
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S
 – Structural validity; H – Hypothesis validity; C – Cross-cultural validity 
*
 
As a translated version cannot be analysed alongside the other PROM
 
** As this measure has components of PRO and CRO measures this cannot be analysed alongside the other PROM 
 
  
Harrison et al., 1995 _ Poor _ _ Poor _ 
VAS-W 
      
Bennell et al., 2000 _ Poor Poor GoodS _ _ 
Crossley et al., 2004 _ Poor _ _ Poor _ 
Harrison et al., 1995 _ Poor _ _ Poor _ 
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Table 5   
Quality of measurement properties per questionnaire 
 Measurement Properties  
 Internal Consistency Test-retest 
Reliability 
Measurement  
Error 
Validity Responsiveness Interpretability 
ADLS 
 
nr nr nr nr ? nr 
EPQ 
 
nr ? ? ++S ? nr 
Flandry 
 
nr ? ? ++ S nr nr 
Kujala/AKPS  
 
nr ? ? ++ S ? nr 
MFIQ 
 
? ? ? ++ S ? nr 
PSS 
 
? nr nr nr nr nr 
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Abbreviations: S – Structural validity; H – Hypothesis validity; C – Cross-cultural validity; nr – not reported. 
Evidence grading: +++ or --- ‘strong’ evidence of a positive/negative result, ++ or -- ‘moderate’ evidence of a positive/negative result, + or - 
‘limited’ evidence of a positive/negative result, ± ‘conflicting’ evidence, ? unknown due to poor methodological quality. 
‡  Measured against SF 36 physical. 
*
 
Translated version of Kujala questionnaire.
 
** Measure has PRO and CRO components. 
VAS/ Numeric Pain 
Rating Scale 
 
nr ? nr nr ? nr 
VAS-L 
 
nr ? nr nr ? nr 
VAS-U 
 
nr ? ? ++ S ? nr 
VAS-W 
 
nr ? ?  ++ S ? nr 
Persian Version 
Kujala * 
 
? + nr +H,C,‡ nr nr 
PFS ** 
 
? nr nr nr  ? nr 
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Records identified via databases after 679 
duplicates removed (n=2177): 
- MEDLINE (n=221) 
- EMBASE (n=141) 
- AMED/CINHAL+ (n=1675) 
- COCHRANE (n=140) 
Number of records screened (n=2177): 
- Kappa=0.682 (95% CI 0.557 to 0.806) 
Excluded by title/abstract (n=2150) 
Number of full-text articles assessed for 
eligibility (n=22): 
- Agreement: 100% 
Full-text articles excluded (n=15), reason: 
- Non-PFPS cohort (n=3) 
- PFPS not major complaint (n=1) 
- PFPS diagnostic criteria absent or not fulfilled (n=8) 
- Conference abstract (n=2) 
- No PROM (n=1) 
Number of additional full-text articles included 
following the hand search of reference lists and 
the citation search (n=0) 
Final number of full-text articles included in the 
analysis (n=7) 
Fig. 1. Flow Diagram of Searches 
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APPENDIX I 
 
MEDLINE search strategy Aug 2013 
 
1. knee joint or knee or patella or patellofemoral.mp 
2. arthralgia or pain.mp 
3. Combine 1. And 2. 
4. anterior knee pain.mp 
5. ((patell$ or femoropatell$ or femoro-patell$ or retropatell$) adj (pain or syndrome or 
dysfunction)).mp. [mp = title, original title, abstract, name of substance word, subject 
heading word] 
6. ((lateral compression or lateral facet or lateral pressure or odd facet) adj (pain or 
syndrome or dysfunction)).mp.  [mp = title, original title, abstract, name of substance 
word, subject heading word] 
7. ((chondromalac$ or chondropath$) adj (knee$ or patell$ or femoropatell$ or femoro-
patell$ or retropatell$)).mp. [mp = title, original title, abstract, name of substance word, 
subject heading word] 
8. or/3-7 
9. Clinometric/ or Psychometric.mp (clinomet$/ or psychometr$.mp) 
10. (Reliability/ or reliable).mp  
11. Validity adj (content or construct or criterion).mp 
12. Responsiveness.mp 
13. clinical sensitivity.mp 
14. Internal adj consistency.mp 
1. Measurement adj error.mp 
2. Interpretability.mp 
17. or/9-16. 
18. outcome measur$.mp 
19. Questionnair$.mp 
20. (patient reported or patient-reported or self-reported) adj (questionnair$ or scale or 
measure or outcome or outcome measure$).mp 
21. (clinician reported or clinician-reported or performance based or performance-based) 
adj (questionnair$ or scale or measure or outcome ot outcome measur$).mp 
22. or/ 18-21 
23.  8 and 17 and 22 
24. Limit 23 (humans) 
 
